SOUTHWEST ONCOLOGY GROUP--CLINICAL TRIALS

西南肿瘤集团--临床试验

• 批准号: 6489269
• 负责人: HOWARD OZER
• 金额: $ 6.2万
• 依托单位: UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
• 依托单位国家: 美国
• 财政年份: 1993
• 资助国家: 美国
• 起止时间: 1993-05-24 至 2003-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6489269
• 关键词: antineoplastics; bleomycin; bone marrow transplantation; brain neoplasms; breast neoplasms; cancer information system; cancer prevention; cancer registry /resource; cis platinum compound; clinical research; clinical trials; combination cancer therapy; combination chemotherapy; cooperative study; cyclophosphamide; doxorubicin; drug resistance; female reproductive system neoplasm; fludarabine; gastrointestinal neoplasms; head /neck neoplasm; hormone therapy; human subject; human therapy evaluation; ifosfamide; leukemia; lung neoplasms; lymphoma; meeting /conference /symposium; melanoma; multiple myeloma; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer epidemiology; neoplasm /cancer genetics; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; oncology nursing; paclitaxel; pancreas neoplasms; pathology; prognosis; prostate neoplasms; quality of life; sarcoma; tamoxifen; tissue resource /registry; urinary tract neoplasms; women's health

Participation in the Southwest Oncology Group (SWOG) has been a major part of the clinical investigative effort of the section of Hematology- Oncology in the Department of Medicine at the University of Oklahoma Health Sciences Center (OUHSC). This effort results in the enrollment of a consistent number of eligible and evaluable patients into SWOG trials. SWOG protocols at the University of Oklahoma provide the major opportunity for Oklahoma residents to participate in large scale, well designed clinical trials. Patients are accrued via both the parent institution and affiliated CGOPs. Most patients in the state, including a large number of Native Americans and rural Oklahomans, are treated by physicians who are part of this network. Annual accrual for the entire network has been ninety-seven patients. We have been working to increase our involvement in the scholarly aspects of clinical trials. At the member institution, we have focused our efforts in five areas including breast cancer, head and neck cancer, genitourinary cancer, lung cancer, and hematological malignancies. This effort has resulted in the establishment of multidisciplinary programs in these areas which has helped to facilitate identification and enrollment of patients on SWOG protocols. In addition, it has allowed for the development of in-house protocols which might serve as pilot studies for future SWOG trials.

参与西南肿瘤学小组（SWOG）一直是主要的 血液学部分的临床研究工作的一部分 - 俄克拉荷马大学医学系的肿瘤学 健康科学中心（OUHSC）。 这项工作导致入学 一致数量的合格和可评估患者陷入困境 试验。 俄克拉荷马大学的Swog协议提供了专业 俄克拉荷马州居民大规模参加的机会 设计临床试验。 患者都是通过父母两者累的 机构和附属CGOP。 该州的大多数患者，包括 许多美洲原住民和俄克拉荷马人都受到 是该网络的一部分的医师。 整个年度应计 网络已有97名患者。 我们一直在努力增加参与学术的参与 临床试验的各个方面。 在会员机构，我们专注于 我们在包括乳腺癌，头颈癌等五个领域的努力， 泌尿生殖器癌，肺癌和血液系统恶性肿瘤。 这 努力导致建立了多学科计划 在这些领域，有助于促进识别和 患者在Swog方案中注册。 此外，它允许 为了制定内部协议，可能是飞行员 研究未来的Swog试验。